Literature DB >> 10376526

Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation.

F E Jones1, D F Stern.   

Abstract

Overexpression of the receptor tyrosine kinase ErbB2/HER2/Neu (ErbB2) occurs in 15-40% of human breast cancers. To determine the function of ErbB2 signaling during normal mouse mammary gland development, we expressed a carboxyl-terminal truncated dominant negative allele of ErbB2 (ErbB2deltaIC) in the developing mouse mammary gland. Despite ErbB2deltaIC expression within mammary glands of pubescent virgin and pregnant mice, a phenotype was not observed until late in pregnancy. At 1 day post-partum, lactationally active, distended lobuloalveoli failed to form. This phenotype was exaggerated in multiparous females expressing ErbB2deltaIC. Immunohistochemical staining for ErbB2deltaIC revealed a concordance between high levels of ErbB2deltaIC protein expression and the absence of lactational products within the lumens of ErbB2deltaIC stained lobuloalveoli. These results demonstrate that ErbB2 signaling is required for proper mammary development and lactation at parturition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376526     DOI: 10.1038/sj.onc.1202698

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.

Authors:  C M Ellis; M J Dyson; T J Stephenson; E L Maltby
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

3.  Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways.

Authors:  Chien-Chung Chen; Douglas B Stairs; Robert B Boxer; George K Belka; Nelson D Horseman; James V Alvarez; Lewis A Chodosh
Journal:  Genes Dev       Date:  2012-10-01       Impact factor: 11.361

Review 4.  Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network.

Authors:  K L Troyer; D C Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

5.  Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.

Authors:  K M Ferguson; P J Darling; M J Mohan; T L Macatee; M A Lemmon
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

6.  Neuregulin 1-erbB2 signaling is required for the establishment of radial glia and their transformation into astrocytes in cerebral cortex.

Authors:  Ralf S Schmid; Barbara McGrath; Bridget E Berechid; Becky Boyles; Mark Marchionni; Nenad Sestan; Eva S Anton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-20       Impact factor: 11.205

7.  Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin.

Authors:  Mark D Sternlicht; Susan W Sunnarborg; Hosein Kouros-Mehr; Ying Yu; David C Lee; Zena Werb
Journal:  Development       Date:  2005-08-03       Impact factor: 6.868

Review 8.  ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Authors:  David F Stern
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

9.  Targeting HER2 in breast cancer: overview of long-term experience.

Authors:  Evan Lantz; Ivan Cunningham; Gerald M Higa
Journal:  Int J Womens Health       Date:  2010-08-09

Review 10.  The ADAM17-amphiregulin-EGFR axis in mammary development and cancer.

Authors:  Mark D Sternlicht; Susan W Sunnarborg
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-10       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.